Events

ASMBR 2018

 

September 2018- Entera presented "An oral PTH(1-34) formulation with a pharmacokinetic profile optimized for the treatment of osteoporosis" for its Osteoporosis drug at the annual meeting of ASBMR (The American Society of Bone and Mineral Research) in Montreal Canada. Osteoporosis is a disease that causes bones to become less dense and more fragile which increases the risk of fractures. Entera presented results from a clinical study comparing the commercial SC injection of PTH(1-34) to Entera’s oral formulation (EB613) designed to have a shorter drug exposure, potentially enhancing its anabolic effect on the bone.

pdf See poster

ASMBR 2017

September 2017- Entera presents the "Enhanced bioavailability and reduced absorption variability of Oral PTH 1-34 in men" for its hypoparathyroidism drug at the annual meeting of ASBMR (The American Society of Bone and Mineral Research) in Denver,Colorado. Primary hypoparathyroidism (PHP) is a hormone deficiency for which no oral replacement therapy is currently available. Oral PTH administration may allow for more flexibility in providing an adequate therapeutic dose, for achievement of normocalemia and normophosphatemia in patients with varied severity of hormone deficiency and response to therapy. Entera presented results from a clinical study focusing more on the control of the drug absorption while minimizing its variability. These results utilized the novel formulation technology in our oral PTH 1-34 tablets with decreased inter-subject variability and significantly increased bioavailability.

pdfSee poster

ASMBR 2016

October 2016- Entera presents the "Novel Oral PTH (1-34) formulation with reduced pharmacokinetic variability" for its hypoparathyroidism drug at the annual meeting of ASBMR (The American Society of Bone and Mineral Research) in Atlanta, Georgia. Primary hypoparathyroidism (PHP) is a hormone deficiency for which no oral replacement therapy is currently available. Oral PTH administration may allow for more flexibility in providing an adequate therapeutic dose, for achievement of normocalemia and normophosphatemia in patients with varied severity of hormone deficiency and response to therapy. Entera presented results from a clinical study utilizing the novel formulation technology in its Oral PTH 1-34) with with decreased inter-subject variability and an absorption profile close to that of the commercially available injectable PTH (1-34).

pdfSee poster

ASBMR 2015

October 2015 - Entera presents the "Oral PTH (1-34) in the Treatment of Hypoparathyroidism" for its hypoparathyroidism drug at the annual meeting of ASBMR (The American Society of Bone and Mineral Research) in Seattle, Washington. Primary hypoparathyroidism (PHP) is a hormone deficiency for which no oral replacement therapy is currently available. Oral PTH administration may allow for more flexibility in providing an adequate therapeutic dose, for achievement of normocalemia and normophosphatemia in patients with varied severity of hormone deficiency and response to therapy. Entera presented the results of its Phase 2a clinical study.
Despite not having an optimization period and the relatively short treatment duration (4 months) Entera Bio’s Oral PTH has shown clear safety and efficacy.

pdfSee poster

ASBMR 2014

September 2014 - Entera presents the "First in Man Studies of Pharmacokinetic Profiles of Novel Oral Parathyroide Hormone PTH (1-34) Delivery System" for its osteoporosis drug at the annual meeting of ASBMR (The American Society of Bone and Mineral Research) in Houston, Texas. PK profiles showed that a single oral dose of PTH(1-34) is rapidly absorbed, and there is no significant difference in Cmax and Tmax when compared with the commercial injection. A transient increase in plasma cAMP was seen in all subjects in response to PTH (1-34) treatments. Increases in cAMP is indicative of PTH bio-activity, suggesting that the administered peptide is pharmacologically active and not degraded during GI transport.

pdfSee poster

ASBMR 2013

October 2013 - Entera presents the "PTH 1-34 Delivered Orally with Novel Drug Delivery Technology - First in Human Results" for its osteoporosis drug at the annual meeting of ASBMR (The American Society of Bone and Mineral Research) in Baltimore, Maryland. PTH 1-34 administered orally to healthy volunteers demonstrates consistent enteral absorption with a PK profile characterized by a rapid Tmax and rapid elimination to optimally simulate the desired PTH profile required for its anabolic effect. A dose escalation and optimization of the formulation was performed showing control of Cmax and variability.

pdfSee poster

ASBMR 2012

October 2012 - Entera presents the "Pharmacokinetics of Novel Oral PTH 1-34 Dosage Form (Tablet) in Rodents" for its Osteoporosis drug at the annual meeting of ASBMR (The American Society of Bone and Mineral Research) in Minneapolis, Minnesota. PTH 1-34 administered orally in rodents demonstrates consistent enteral absorption with a PK profile characterized by a rapid Tmax and rapid elimination simulating the desired PTH profile required for its anabolic effect.

pdfSee poster